Background: To determine a new taxane plus platinum treatment regimen for squamous cell carcinoma of the uterine cervix (CSCC), a phase I feasibility study of docetaxel (DTX) plus nedaplatin (CDGP) combination therapy was conducted.
Patients And Methods: Twenty consecutive patients were enrolled into the study. The starting dose of DTX/CDGP was 60 mg/m2 / 80 mg/m2, every 4 weeks for at least three courses and the dose was escalated to 70 mg/m2 / 100 mg/m2. DTX 60 mg/m2 / CDGP 100 mg/m2 was also evaluated as an extra dose level.
Results: Dose-limiting toxicity was granulocytopenia and the maximum tolerated dose was determined as 70 mg/m2 / 100 mg/m2. All 20 patients had measurable disease and a partial response was achieved in 8 (40.0%) patients.
Conclusion: DTX/CDGP therapy appears to be a tolerable regimen for cervical squamous cell carcinoma, even in patients previously treated by cisplatin concurrent chemoradiotherapy. The recommended doses of DTX and CDGP were determined to be 60 mg/m2 and 100 mg/m2, respectively.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.
JAMA
December 2024
Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai.
Article Synopsis
- The study focuses on assessing the effectiveness and side effects of combining camrelizumab, an anti-PD-1 antibody, with chemotherapy for patients with early or locally advanced triple-negative breast cancer.
- The phase 3 trial involved 441 patients from various hospitals in China, where they were randomly assigned to receive either camrelizumab or a placebo along with standard chemotherapy over several weeks.
- Results showed a higher rate of pathological complete response—meaning no invasive tumors were detected—in the camrelizumab group (56.8%) compared to the placebo group (44.7%), indicating camrelizumab may enhance the effectiveness of chemotherapy.
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer: A Nonrandomized Clinical Trial.
JAMA Oncol
December 2024
Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Importance: Current chemotherapy regimens for patients with ERBB2 (formerly HER2)-positive breast cancer are associated with considerable morbidity. These patients may benefit from more effective and less toxic therapies.
Objective: To evaluate the safety, immunogenicity, and preliminary efficacy of intratumoral (IT) delivery of conventional type 1 dendritic cells (cDC1) in combination with ERBB2-targeted therapies.
Efficacy and Safety of Neoadjuvant Immunotherapy Combined with Sandwich Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Retrospective Study.
Onco Targets Ther
November 2024
Department of Radiation Oncology, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, 570311, People's Republic of China.
Article Synopsis
- The study investigated the safety and effectiveness of combining neoadjuvant immunotherapy with sandwich chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma (NPC).
- A total of 37 patients underwent a specific treatment regimen that included multiple cycles of PD-1 inhibitors, chemotherapy, and radiation therapy, showing a high treatment efficiency rate of 94.6% and excellent survival outcomes over two years.
- While neutropenia was common, other severe adverse effects were rare, indicating that this combined treatment approach is beneficial with manageable side effects for NPC patients.
Phase 2, Multicenter, Open-label, Nonrandomized Study of Neoadjuvant Chemotherapy Liposomal Irinotecan With 5-Fluorouracil, Leucovorin, and Oxaliplatin, Followed by Chemoradiotherapy in Patients With Rectal Cancer in a Watch-and-Wait Program.
Am J Clin Oncol
November 2024
HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Hospital Universitario HM Sanchinarro, HM Hospitales.
Objective: To evaluate the efficacy of neoadjuvant chemotherapy combination with liposomal irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin in patients with locally advanced rectal cancer.
Methods: This was a phase 2, nonrandomized, multicenter study in adults with stage II or III rectal cancer and an Eastern Cooperative Oncology Group performance status of 0 to 1. Total neoadjuvant therapy (TNT) consisted of neoadjuvant chemotherapy combination with liposomal irinotecan (60 mg/m2), oxaliplatin (60 mg/m2), leucovorin (400 mg/m2), and fluorouracil (2400 mg/m²), followed by chemoradiotherapy [ie, capecitabine (825 mg/m2) and radiotherapy according to the standard of care].
Treatment Outcomes and Patterns of Disease Recurrence of Patients with Carcinoma of the Buccal Mucosa.
Indian J Otolaryngol Head Neck Surg
December 2024
Department of Radiotherapy, M L N Medical College, Prayagraj, Uttar Pradesh India.
Article Synopsis
- The study focuses on treating locally advanced buccal mucosa cancer, primarily through surgery and postoperative radiotherapy with specific chemotherapy regimens, including Cisplatin and 5-Fluorouracil.
- It evaluates the effectiveness of de-escalated treatment using ipsilateral face radiotherapy, which targets only the affected side of the face to improve functions like chewing and mitigate side effects.
- A total of 54 patients were reviewed retrospectively, revealing treatment patterns and outcomes, including indications for radiation based on tumor margins and lymph node involvement, along with one patient's alternative treatment approach leading to poor outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!